Innate Pharma Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	9.01	20.12	61.64	57.67	24.7
Revenue Growth (YoY)	-55.25%	-67.36%	6.88%	133.47%	-64.59%
Gross Profit	9.01	20.12	61.64	57.67	24.7
Selling, General & Admin	19.39	19.72	18.29	22.44	25.52
Research & Development	43.62	51.98	56.02	51.66	47
Other Operating Expenses	-	-	-	41	-
Total Operating Expenses	63.01	71.7	74.31	115.1	72.53
Operating Income	-54.01	-51.58	-12.67	-57.43	-47.83
Interest Income	7.95	6.08	6.93	4.78	6.34
Interest Expense	-3.12	-3.98	-1.84	-5.32	-4
Total Non-Operating Income (Expense)	4.83	2.1	5.1	-0.55	2.35
Pretax Income	-49.18	-49.47	-7.57	-57.97	-45.48
Net Income	-49.18	-49.47	-7.57	-57.97	-45.48
Earnings From Discontinued Operations	-	-	-	-0.13	-7.33
Net Income to Common	-49.18	-49.47	-7.57	-58.1	-52.81
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	90	81	80	80	80
Shares Outstanding (Diluted)	90	81	80	80	80
Shares Change (YoY)	10.54%	0.74%	1.02%	0.12%	0.77%
EPS (Basic)	-0.55	-0.61	-0.09	-0.73	-0.66
EPS (Diluted)	-0.55	-0.61	-0.09	-0.73	-0.66
EPS Growth	-	-	-	-	-
Free Cash Flow	-52.9	-7.29	-32.91	-19.69	-59.39
Free Cash Flow Growth	-	-	-	-	-
Free Cash Flow Per Share	-0.59	-0.09	-0.41	-0.25	-0.75
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-599.76%	-256.32%	-20.55%	-99.57%	-193.60%
Profit Margin	-546.11%	-245.87%	-12.28%	-100.52%	-184.10%
FCF Margin	-587.40%	-36.22%	-53.39%	-34.14%	-240.40%
EBITDA	-52.62	-49.58	-7.58	-12.02	-43.23
EBITDA Margin	-584.39%	-246.41%	-12.29%	-20.84%	-174.99%
EBIT	-54.01	-51.58	-12.67	-57.43	-47.83
EBIT Margin	-599.76%	-256.32%	-20.55%	-99.57%	-193.60%

SEC Filings: 10-K · 10-Q